This company has shut down. Novome Biotechnologies is no longer operating — its last tracked round was a Series B in 2022.
Explore the Startup GraveyardNovome Biotechnologies is a biotechnology company focused on engineering defined activities into the human.
Novome Biotechnologies has raised $43.5M in total funding. The most recent round was Series B. The last funding was announced in September 2022.
Novome Biotechnologies's investors include Tencent, DCVC Bio, National Science Foundation, Alexandria Venture Investments, 5AM Ventures.
Novome Biotechnologies is headquartered in South San Francisco, United States.
Novome Biotechnologies is a biotechnology company focused on engineering defined activities into the human.
Novome Biotechnologies is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Novome Biotechnologies — Funding & Investors." VCBacked, September 13, 2022, https://www.vcbacked.co/company/novome-biotechnologies. Accessed July 19, 2026.
VCBacked. (2022). Novome Biotechnologies — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/novome-biotechnologies
{{cite web |title=Novome Biotechnologies — Funding & Investors |url=https://www.vcbacked.co/company/novome-biotechnologies |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated